News about "Antibody Degraducer Conjugates"

Debiopharm, Ubix Therapeutics ink research pact to develop new drug modality known as Antibody Degraducer Conjugates

Debiopharm, Ubix Therapeutics ink research pact to develop new drug modality known as Antibody Degraducer Conjugates

Debiopharm, a Swiss-based global biopharmaceutical company, and Ubix Therapeutics, a South Korea-based biotech company, announced their co-research agreement combining two novel proprietary technologies to specifically target cancer cells

Antibody Degraducer Conjugates | 17/06/2021 | By Darshana 331


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members